Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

A novel platform for in vivo detection of cytokine release within discrete brain regions.

Zhang K, Baratta MV, Liu G, Frank MG, Leslie NR, Watkins LR, Maier SF, Hutchinson MR, Goldys EM.

Brain Behav Immun. 2018 Apr 17. pii: S0889-1591(18)30130-2. doi: 10.1016/j.bbi.2018.04.011. [Epub ahead of print]

PMID:
29678795
2.

Identification of a PTEN mutation with reduced protein stability, phosphatase activity, and nuclear localization in Hong Kong patients with autistic features, neurodevelopmental delays, and macrocephaly.

Wong CW, Or PMY, Wang Y, Li L, Li J, Yan M, Cao Y, Luk HM, Tong TMF, Leslie NR, Lo IF, Choy KW, Chan AML.

Autism Res. 2018 Apr 2. doi: 10.1002/aur.1950. [Epub ahead of print]

PMID:
29608813
3.

A simple and robust real-time qPCR method for the detection of PIK3CA mutations.

Alvarez-Garcia V, Bartos C, Keraite I, Trivedi U, Brennan PM, Kersaudy-Kerhoas M, Gharbi K, Oikonomidou O, Leslie NR.

Sci Rep. 2018 Mar 9;8(1):4290. doi: 10.1038/s41598-018-22473-9.

4.

Behavioural and neural sequelae of stressor exposure are not modulated by controllability in females.

Baratta MV, Leslie NR, Fallon IP, Dolzani SD, Chun LE, Tamalunas AM, Watkins LR, Maier SF.

Eur J Neurosci. 2018 Apr;47(8):959-967. doi: 10.1111/ejn.13833. Epub 2018 Feb 5.

PMID:
29359831
5.

GSK3 and its interactions with the PI3K/AKT/mTOR signalling network.

Hermida MA, Dinesh Kumar J, Leslie NR.

Adv Biol Regul. 2017 Aug;65:5-15. doi: 10.1016/j.jbior.2017.06.003. Epub 2017 Jun 27. Review.

PMID:
28712664
6.

Importin-11 keeps PTEN safe from harm.

Leslie NR.

J Cell Biol. 2017 Mar 6;216(3):539-541. doi: 10.1083/jcb.201612014. Epub 2017 Feb 13.

7.

Prostate cancer, PI3K, PTEN and prognosis.

Wise HM, Hermida MA, Leslie NR.

Clin Sci (Lond). 2017 Feb 1;131(3):197-210. doi: 10.1042/CS20160026. Review.

PMID:
28057891
8.

Assays to Measure PTEN Lipid Phosphatase Activity In Vitro from Purified Enzyme or Immunoprecipitates.

Spinelli L, Leslie NR.

Methods Mol Biol. 2016;1447:95-105. doi: 10.1007/978-1-4939-3746-2_6.

PMID:
27514802
9.

Controlling PTEN (Phosphatase and Tensin Homolog) Stability: A DOMINANT ROLE FOR LYSINE 66.

Gupta A, Leslie NR.

J Biol Chem. 2016 Aug 26;291(35):18465-73. doi: 10.1074/jbc.M116.727750. Epub 2016 Jul 12.

10.

In Cell and In Vitro Assays to Measure PTEN Ubiquitination.

Gupta A, Maccario H, Kriplani N, Leslie NR.

Methods Mol Biol. 2016;1388:155-65. doi: 10.1007/978-1-4939-3299-3_11.

PMID:
27033076
11.

The PTEN protein: cellular localization and post-translational regulation.

Leslie NR, Kriplani N, Hermida MA, Alvarez-Garcia V, Wise HM.

Biochem Soc Trans. 2016 Feb;44(1):273-8. doi: 10.1042/BST20150224. Review.

PMID:
26862215
12.

Inherited PTEN mutations and the prediction of phenotype.

Leslie NR, Longy M.

Semin Cell Dev Biol. 2016 Apr;52:30-8. doi: 10.1016/j.semcdb.2016.01.030. Epub 2016 Jan 28. Review.

13.

Three-dimensional bioprinting of complex cell laden alginate hydrogel structures.

Tabriz AG, Hermida MA, Leslie NR, Shu W.

Biofabrication. 2015 Dec 21;7(4):045012. doi: 10.1088/1758-5090/7/4/045012.

PMID:
26689257
14.

Class I PI 3-kinases: Function and evolution.

Kriplani N, Hermida MA, Brown ER, Leslie NR.

Adv Biol Regul. 2015 Sep;59:53-64. doi: 10.1016/j.jbior.2015.05.002. Epub 2015 Jun 20. Review.

PMID:
26159297
15.

Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.

Spinelli L, Black FM, Berg JN, Eickholt BJ, Leslie NR.

J Med Genet. 2015 Feb;52(2):128-34. doi: 10.1136/jmedgenet-2014-102803. Epub 2014 Dec 19.

16.

Assaying PTEN catalysis in vitro.

Spinelli L, Leslie NR.

Methods. 2015 May;77-78:51-7. doi: 10.1016/j.ymeth.2014.11.003. Epub 2014 Nov 13.

PMID:
25461809
17.

Yeast-based methods to assess PTEN phosphoinositide phosphatase activity in vivo.

Rodríguez-Escudero I, Fernández-Acero T, Bravo I, Leslie NR, Pulido R, Molina M, Cid VJ.

Methods. 2015 May;77-78:172-9. doi: 10.1016/j.ymeth.2014.10.020. Epub 2014 Oct 25. Review.

PMID:
25448481
18.

PTEN inhibitors: an evaluation of current compounds.

Spinelli L, Lindsay YE, Leslie NR.

Adv Biol Regul. 2015 Jan;57:102-11. doi: 10.1016/j.jbior.2014.09.012. Epub 2014 Oct 2.

PMID:
25446882
19.

A unified nomenclature and amino acid numbering for human PTEN.

Pulido R, Baker SJ, Barata JT, Carracedo A, Cid VJ, Chin-Sang ID, Davé V, den Hertog J, Devreotes P, Eickholt BJ, Eng C, Furnari FB, Georgescu MM, Gericke A, Hopkins B, Jiang X, Lee SR, Lösche M, Malaney P, Matias-Guiu X, Molina M, Pandolfi PP, Parsons R, Pinton P, Rivas C, Rocha RM, Rodríguez MS, Ross AH, Serrano M, Stambolic V, Stiles B, Suzuki A, Tan SS, Tonks NK, Trotman LC, Wolff N, Woscholski R, Wu H, Leslie NR.

Sci Signal. 2014 Jul 1;7(332):pe15. doi: 10.1126/scisignal.2005560.

20.

Mutant PTEN in Cancer: Worse Than Nothing.

Leslie NR, den Hertog J.

Cell. 2014 Apr 24;157(3):527-9. doi: 10.1016/j.cell.2014.04.008.

21.

Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells.

Hawley SA, Ross FA, Gowans GJ, Tibarewal P, Leslie NR, Hardie DG.

Biochem J. 2014 Apr 15;459(2):275-87. doi: 10.1042/BJ20131344.

22.

Cross talk between the Akt and p38α pathways in macrophages downstream of Toll-like receptor signaling.

McGuire VA, Gray A, Monk CE, Santos SG, Lee K, Aubareda A, Crowe J, Ronkina N, Schwermann J, Batty IH, Leslie NR, Dean JL, O'Keefe SJ, Boothby M, Gaestel M, Arthur JS.

Mol Cell Biol. 2013 Nov;33(21):4152-65. doi: 10.1128/MCB.01691-12. Epub 2013 Aug 26.

23.

MC1R is a potent regulator of PTEN after UV exposure in melanocytes.

Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, Wang Y, Leslie NR, Xu GX, Widlund HR, Ryu B, Alani RM, Dutton-Regester K, Goding CR, Hayward NK, Wei W, Cui R.

Mol Cell. 2013 Aug 22;51(4):409-22. doi: 10.1016/j.molcel.2013.08.010.

24.

Phosphorylation of the actin binding protein Drebrin at S647 is regulated by neuronal activity and PTEN.

Kreis P, Hendricusdottir R, Kay L, Papageorgiou IE, van Diepen M, Mack T, Ryves J, Harwood A, Leslie NR, Kann O, Parsons M, Eickholt BJ.

PLoS One. 2013 Aug 5;8(8):e71957. doi: 10.1371/journal.pone.0071957. Print 2013.

25.

PDK1 controls upstream PI3K expression and PIP3 generation.

Dieterle AM, Böhler P, Keppeler H, Alers S, Berleth N, Drießen S, Hieke N, Pietkiewicz S, Löffler AS, Peter C, Gray A, Leslie NR, Shinohara H, Kurosaki T, Engelke M, Wienands J, Bonin M, Wesselborg S, Stork B.

Oncogene. 2014 Jun 5;33(23):3043-53. doi: 10.1038/onc.2013.266. Epub 2013 Jul 29.

PMID:
23893244
26.

Cell biology. Where is PTEN?

Leslie NR, Brunton VG.

Science. 2013 Jul 26;341(6144):355-6. doi: 10.1126/science.1242541. No abstract available.

PMID:
23888029
27.

PtdIns(4,5)P2-mediated cell signaling: emerging principles and PTEN as a paradigm for regulatory mechanism.

Gericke A, Leslie NR, Lösche M, Ross AH.

Adv Exp Med Biol. 2013;991:85-104. doi: 10.1007/978-94-007-6331-9_6. Review.

28.

C1-Ten is a protein tyrosine phosphatase of insulin receptor substrate 1 (IRS-1), regulating IRS-1 stability and muscle atrophy.

Koh A, Lee MN, Yang YR, Jeong H, Ghim J, Noh J, Kim J, Ryu D, Park S, Song P, Koo SH, Leslie NR, Berggren PO, Choi JH, Suh PG, Ryu SH.

Mol Cell Biol. 2013 Apr;33(8):1608-20. doi: 10.1128/MCB.01447-12. Epub 2013 Feb 11.

29.

PTEN: an intercellular peacekeeper?

Leslie NR.

Sci Signal. 2012 Nov 13;5(250):pe50. doi: 10.1126/scisignal.2003685. Review.

PMID:
23150879
30.

Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110α/PIK3CA but not by HER2 or mutant AKT1.

Berglund FM, Weerasinghe NR, Davidson L, Lim JC, Eickholt BJ, Leslie NR.

Oncogene. 2013 Sep 12;32(37):4417-26. doi: 10.1038/onc.2012.459. Epub 2012 Oct 22.

31.

IQGAP proteins reveal an atypical phosphoinositide (aPI) binding domain with a pseudo C2 domain fold.

Dixon MJ, Gray A, Schenning M, Agacan M, Tempel W, Tong Y, Nedyalkova L, Park HW, Leslie NR, van Aalten DM, Downes CP, Batty IH.

J Biol Chem. 2012 Jun 29;287(27):22483-96. doi: 10.1074/jbc.M112.352773. Epub 2012 Apr 5.

32.

The PTEN and Myotubularin phosphoinositide 3-phosphatases: linking lipid signalling to human disease.

Davies EM, Sheffield DA, Tibarewal P, Fedele CG, Mitchell CA, Leslie NR.

Subcell Biochem. 2012;58:281-336. doi: 10.1007/978-94-007-3012-0_8.

PMID:
22403079
33.

PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity.

Tibarewal P, Zilidis G, Spinelli L, Schurch N, Maccario H, Gray A, Perera NM, Davidson L, Barton GJ, Leslie NR.

Sci Signal. 2012 Feb 28;5(213):ra18. doi: 10.1126/scisignal.2002138.

34.

Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases.

Leslie NR, Dixon MJ, Schenning M, Gray A, Batty IH.

Adv Biol Regul. 2012 Jan;52(1):205-13. Review. No abstract available.

PMID:
21930147
35.

A screen for novel phosphoinositide 3-kinase effector proteins.

Dixon MJ, Gray A, Boisvert FM, Agacan M, Morrice NA, Gourlay R, Leslie NR, Downes CP, Batty IH.

Mol Cell Proteomics. 2011 Apr;10(4):M110.003178. doi: 10.1074/mcp.M110.003178. Epub 2011 Jan 24.

36.

Non-genomic loss of PTEN function in cancer: not in my genes.

Leslie NR, Foti M.

Trends Pharmacol Sci. 2011 Mar;32(3):131-40. doi: 10.1016/j.tips.2010.12.005. Epub 2011 Jan 13. Review.

PMID:
21236500
37.

Mechanism of activation of PKB/Akt by the protein phosphatase inhibitor Calyculin A.

Pozuelo-Rubio M, Leslie NR, Murphy J, Mackintosh C.

Cell Biochem Biophys. 2010 Dec;58(3):147-56. doi: 10.1007/s12013-010-9101-4.

38.

Migration Stimulating Factor (MSF) promotes fibroblast migration by inhibiting AKT.

Ellis IR, Jones SJ, Lindsay Y, Ohe G, Schor AM, Schor SL, Leslie NR.

Cell Signal. 2010 Nov;22(11):1655-9. doi: 10.1016/j.cellsig.2010.06.005. Epub 2010 Jul 1.

PMID:
20600851
39.

Leptin regulates AMPA receptor trafficking via PTEN inhibition.

Moult PR, Cross A, Santos SD, Carvalho AL, Lindsay Y, Connolly CN, Irving AJ, Leslie NR, Harvey J.

J Neurosci. 2010 Mar 17;30(11):4088-101. doi: 10.1523/JNEUROSCI.3614-09.2010.

40.

Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress.

Maccario H, Perera NM, Gray A, Downes CP, Leslie NR.

J Biol Chem. 2010 Apr 23;285(17):12620-8. doi: 10.1074/jbc.M109.072280. Epub 2010 Feb 22.

41.

Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN.

Davidson L, Maccario H, Perera NM, Yang X, Spinelli L, Tibarewal P, Glancy B, Gray A, Weijer CJ, Downes CP, Leslie NR.

Oncogene. 2010 Feb 4;29(5):687-97. doi: 10.1038/onc.2009.384. Epub 2009 Nov 16.

42.

Indirect mechanisms of carcinogenesis via downregulation of PTEN function.

Leslie NR, Spinelli L, Tibarewal P, Zilidis G, Weerasinghe N, Lim JC, Maccario H, Downes CP.

Adv Enzyme Regul. 2010;50(1):112-8. doi: 10.1016/j.advenzreg.2009.10.015. Epub 2009 Nov 4. Review. No abstract available.

PMID:
19895830
43.

P-REX2a driving tumorigenesis by PTEN inhibition.

Leslie NR.

Sci Signal. 2009 Oct 27;2(94):pe68. doi: 10.1126/scisignal.294pe68.

PMID:
19861688
44.

MyosinV controls PTEN function and neuronal cell size.

van Diepen MT, Parsons M, Downes CP, Leslie NR, Hindges R, Eickholt BJ.

Nat Cell Biol. 2009 Oct;11(10):1191-6. doi: 10.1038/ncb1961. Epub 2009 Sep 20. Erratum in: Nat Cell Biol. 2009 Nov;11(11):1387.

45.

Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity.

Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C, Neumann CA.

EMBO J. 2009 May 20;28(10):1505-17. doi: 10.1038/emboj.2009.101. Epub 2009 Apr 16.

46.

The significance of PTEN's protein phosphatase activity.

Leslie NR, Maccario H, Spinelli L, Davidson L.

Adv Enzyme Regul. 2009;49(1):190-6. doi: 10.1016/j.advenzreg.2008.12.002. Epub 2008 Dec 31. Review. No abstract available.

PMID:
19168090
47.

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.

Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA, Barata JT.

J Clin Invest. 2008 Nov;118(11):3762-74. doi: 10.1172/JCI34616. Epub 2008 Oct 1.

48.

Understanding PTEN regulation: PIP2, polarity and protein stability.

Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP.

Oncogene. 2008 Sep 18;27(41):5464-76. doi: 10.1038/onc.2008.243. Review.

PMID:
18794881
49.

Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake.

Green CJ, Göransson O, Kular GS, Leslie NR, Gray A, Alessi DR, Sakamoto K, Hundal HS.

J Biol Chem. 2008 Oct 10;283(41):27653-67. doi: 10.1074/jbc.M802623200. Epub 2008 Jul 31.

50.

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA, McCubrey JA.

Oncogene. 2008 Jul 3;27(29):4086-95. doi: 10.1038/onc.2008.49. Epub 2008 Mar 10.

Supplemental Content

Loading ...
Support Center